-

Eurofins and Rite Aid Launch an Over-the-Counter, FDA-Authorised, at-Home COVID-19 PCR Test in all Rite Aid Locations in the U.S.

LUXEMBOURG--(BUSINESS WIRE)--Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit. The co-branded kits, available at all Rite Aid stores across 17 states in the USA, will offer customers a convenient way to test for the virus from their home and will detect the virus in symptomatic and asymptomatic patients.

The at-home COVID-19 nasal PCR kit is among the first over-the-counter at-home test kits for SARS-CoV-2 to receive US Food and Drug Administration Emergency Use Authorization (EUA). The test was developed by Eurofins Viracor, a leading infectious disease testing laboratory, and is based on its FDA EUA authorised SARS-CoV-2 RT-PCR assay. As of December 2020, this later assay offers one of the best sensitivity rates of 117 laboratories that have submitted results to the FDA’s SARS-CoV-2 Reference Panel; https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data#results.

Eurofins’ CEO, Gilles Martin commented: "We are excited to partner with Rite Aid and launch this at-home COVID-19 testing kit, making access to test kits widely available to people across the U.S through Rite Aid’s national network. Increasing population testing rates is an important step in fighting the pandemic, and its new more infectious variants, and building the confidence needed to accelerate a return to everyday life.”

[1]This home-collection kit has not been FDA cleared or approved; rather it has been authorised by FDA under an EUA only for the home collection and maintenance of nasal swab specimens as an aid in detection of nucleic acid from SARS-CoV-2, and not for any other viruses or pathogens, and only for the duration of the declaration that circumstances exist justifying the authorisation of emergency use of medical devices under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.Eurofins Shares are listed on Euronext Paris Stock Exchange.

About empowerDX
empowerDX is the online shop for easy at-home health testing. empowerDX specializes in FDA-authorized COVID-19 testing, women’s health, men’s health, sexual health and general wellness testing.

Contacts

Annemarie Watson
ir@eurofins.com

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

Annemarie Watson
ir@eurofins.com

More News From Eurofins Scientific

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF EUROFINS SCIENTIFIC SE – E1013 Identity of t...

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

LANCASTER, Pa.--(BUSINESS WIRE)--Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributin...

Eurofins: Weekly Report on Share Repurchases From 24th November to 28th November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 24/11/2025 FR0014000MR3 20 000 58.4487 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 25/11/2025 FR0014000MR3 20 000 58.6804 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/1...
Back to Newsroom